Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
Conditions
Interventions
Radiation + cisplatin
Radiation + cisplatin + gemcitabine
Locations
12
France
Institut Bergonié
Bordeaux, France
Centre Francois Baclesse
Caen, France
Hopital Henri Mondor
Créteil, France
CRLC GF Leclerc
Dijon, France
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, France
Centre azuréen de Cancérologie
Mougins, France
Start Date
July 6, 2011
Primary Completion Date
July 25, 2022
Completion Date
December 7, 2024
Last Updated
October 10, 2025
Lead Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions